



## INSPIR THERAPEUTICS, INC. (OTCQB: NSPX)

Inspyr Therapeutics, Inc. is a San Antonio-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. Inspyr's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for targeted release of drug candidates within tumors. Inspyr's lead drug candidate, mipsagargin, was granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).

## MANAGEMENT TEAM

### **Russell Richerson, PhD**

COO, Interim Principal Executive Officer, Principal Accounting Officer, and Corporate Secretary

### **Peter E. Grebow, PhD**

Interim Chairman

## RECENT NEWS

### **GenSpera Announces Name Change to Inspyr Therapeutics**

Aug 1 2016, 4:05 PM EDT

### **GenSpera Announces Management Changes**

Mar 22 2016, 5:36 PM EDT

## INSPIR THERAPEUTICS, INC.

2511 N Loop 1604 W  
Suite 204 (3rd Floor)  
San Antonio, TX 78258  
USA

## STOCK OVERVIEW

Symbol	NSPX
Exchange	OTCQB
Shares OS	41,762,356
Market Cap	\$6.06M
Last Price	<b>\$0.145</b>
52-Week Range	<b>\$0.132 - \$0.145</b>
Fiscal Year End	<b>December 31</b>

## INVESTOR RELATIONS

LHA  
Jody Cain  
Senior Vice President  
2121 Avenue of the Stars  
Suite 2970  
Los Angeles, CA 90067  
T: 310-691-7100  
jcain@lhai.com

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.